MPTP administration increases plasma levels of acute phase proteins in non-human primates (Macaca fascicularis)

V. De Pablos, C. Barcia, A. Gomez, F. Ros-Bernal, J. Zamarro-Parra, J. J. Soria-Torrecillas, J. Hernández, J. J. Ceron, M. T. Herrero*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)


Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons in the Substantia Nigra pars compacta (SNpc). Parkinsonian patients and animal models of PD show inflammatory phenomena such as microglial activation and cytokine production that could modulate the progression of the disease, since they play a crucial role in the degenerative process. Since acute phase proteins (APPs) are involved in a number of homeostatic alterations and inflammatory processes, we analyzed the levels of APPs in primates before and after treatment with MPTP. A significant increase in C-reactive protein (CRP), serum amyloid A (SAA) and haptoglobin (HP) levels after MPTP treatment. These results demonstrate that MPTP induces a systemic generalized inflammatory reaction after specific dopaminergic neurotoxicity insult, suggesting that the inflammatory process in Parkinsonism may affect other immune-inflammatory responses outside the brain.

Original languageEnglish
Pages (from-to)37-39
Number of pages3
JournalNeuroscience letters
Issue number1
Publication statusPublished - 29 Sept 2009


  • C-reactive protein (CRP)
  • Dopamine
  • Haptoglobin (HP)
  • Neuroinflammation
  • Neuronal degeneration
  • Parkinson's disease
  • Serum amyloid A (SAA)


Dive into the research topics of 'MPTP administration increases plasma levels of acute phase proteins in non-human primates (Macaca fascicularis)'. Together they form a unique fingerprint.

Cite this